Ascletis Pharma Inc. announced the completion of enrollment in its U.S. Phase IIa clinical study for ASC30, a once-monthly subcutaneous depot formulation of a small molecule GLP-1 receptor agonist for the treatment of obesity. The randomized, double-blind, placebo-controlled, multi-center study enrolled 65 participants who are obese or overweight with at least one weight-related comorbidity. Topline data from the Phase IIa study are expected to be available in the first quarter of 2026. No study results have been presented yet.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.